Indeed, enrichment of these genes were particularly strong in KMT2A-MLLT3 mouse leukemia with NRASG12D and in infant KMT2A-AFF1 ALL patients harboring activating mutations (Supplementary Fig. 9k and Supplementary Data 19, 28)4. This evidence concerns the gene MLLT3 and acute lymphoblastic leukemia.